English
Polski
Español
українська
Indications for bridging
When to use bridging therapy? Do we need it for novel oral anticoagulants?
2017-02-21
When to use bridging therapy? Do we need it for novel oral anticoagulants?
Is hormonal contraception and hormone replacement therapy feasible following an episode of pulmonary thromboembolism or deep vein thrombosis?
In the setting of general medical practice, what is the necessary extent of knowledge on antithrombotic treatment in patients undergoing invasive procedures?
How should we manage a patient who has had a second episode of thrombosis while receiving adequate antithrombotic treatment?
How should we manage patients with a history of gastrointestinal bleeding who require anticoagulant treatment because of a high CHA2DS2-VASc score? Should we prefer novel oral anticoagulants in such patients?
What is the optimal approach to anticoagulant treatment in patients with a high bleeding risk? How should we estimate the bleeding risk and adjust anticoagulant treatment to the bleeding risk?
How can we adequately assess the risk of recurrent thrombosis? What is the Vienna Prediction Model?
Is there an association between novel oral anticoagulants, acute coronary syndromes, and the risk of myocardial infarction?
How to approach a patient treated with novel oral anticoagulants who develops bleeding or in whom an urgent surgery is necessary?
How to manage patients treated with novel oral anticoagulants who require surgery?
